Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Guselkumab loss of exclusitivy?
Campath litigation germany?
Guselkumab patent expiration?
When genetic tenofovir alafenamide be available in us?
Defense strategy against generic in niche market?

How does daurismo treat aml?

See the DrugPatentWatch profile for daurismo

What is Daurismo, and what AML setting is it for?

Daurismo is the brand name for gilteritinib. It is used in acute myeloid leukemia (AML) when the leukemia has a FLT3 mutation. Gilteritinib is intended for patients with relapsed or refractory AML (disease that returns after treatment or does not respond). [1]

How does Daurismo work against AML?

Daurismo targets FLT3 (fms-like tyrosine kinase 3). In AML with FLT3 mutations, FLT3 signaling helps drive leukemia cell growth and survival. By inhibiting FLT3, Daurismo can slow or stop that growth signal in FLT3-mutated AML. [1]

What happens to patients taking it (typical clinical goals)?

For relapsed/refractory FLT3-mutated AML, the treatment goal with Daurismo is to achieve a disease response (such as tumor/leukemia reduction) and improve outcomes compared with other available options for patients with this specific mutation profile. [1]

Who should be tested for before starting Daurismo?

Because Daurismo is aimed at FLT3-driven disease, patients with AML are generally evaluated for FLT3 mutations to confirm eligibility before using gilteritinib. [1]

Is it used with other AML therapies, or alone?

The provided information here focuses on Daurismo as an AML therapy in FLT3-mutated relapsed/refractory disease. Specific combination regimens depend on the clinical protocol and the patient’s situation. [1]

If you share the context you mean (for example, “newly diagnosed FLT3-mutant AML” versus “relapsed FLT3-mutant AML,” or whether you mean a particular line of therapy), I can narrow the explanation to that exact AML setting.

Sources
[1] https://www.drugpatentwatch.com/

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Misaligned

The AI claims primarily describe DAURISMO/gilteritinib for AML with FLT3 mutations and include FLT3 mechanism statements. However, the authoritative labeling content provided is for DAURISMO (glasdegib) and addresses embryo-fetal toxicity/pregnancy risk, not AML/FLT3 indications or gilteritinib. Only the pregnancy/embryo-fetal toxicity concept is supported by the provided labeling excerpt.

Alignment Scorecard

Category	Status	Notes
Indication	Misaligned	Provided labeling is for DAURISMO (glasdegib) pregnancy/embryo-fetal toxicity; AI claims AML/FLT3 use is not supported by provided labeling.
Patient Population	Misaligned	AI specifies relapsed/refractory AML with FLT3 mutation; no such population details are present in the provided labeling excerpt.
Dosage & Administration	Not Addressed	No AI dosage statements; provided excerpt contains pregnancy risk counseling rather than administration instructions for AML.
Contraindications	Not Addressed	Provided excerpt does not include contraindications.
Warnings & Precautions	Partially Aligned	Pregnancy/embryo-fetal toxicity risk warnings are consistent with the provided excerpt, but the AI includes unrelated oncology/FLT3 claims not supported here.
Drug Interactions	Not Addressed	No interaction information provided or claimed in the AI statements.
Adverse Reactions	Not Addressed	Provided excerpt focuses on fetal risk; no adverse reaction claims assessed.
Monitoring	Not Applicable	The provided excerpt includes pregnancy testing guidance; none of the AI FLT3/AML claims address monitoring.
Administration Instructions	Not Addressed	No administration instructions for oncology are present in provided excerpt relevant to the AI claims.
Limitations of Use	Not Addressed	No limitations of use information provided.
Special Populations	Partially Aligned	Embryo-fetal toxicity/pregnancy risk and reproductive potential counseling are supported by the provided excerpt, but AI’s rest is unrelated.

Key Findings

AI’s core oncology claims (AML, FLT3 mutation eligibility, and FLT3 mechanism) are not supported by the provided labeling excerpt.
AI’s claim that DAURISMO is gilteritinib is inconsistent with the provided labeling, which states DAURISMO (glasdegib).
The pregnancy/embryo-fetal toxicity concept in the provided label excerpt is supported (DAURISMO can cause embryo-fetal death or severe birth defects; includes risk mitigation counseling).

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Daurismo is the brand name for gilteritinib.	Contradicted	Provided labeling specifies DAURISMO (glasdegib), not gilteritinib.	High
Daurismo (gilteritinib) is used in acute myeloid leukemia (AML) when the leukemia has an FLT3 mutation.	Not Addressed	Provided excerpt contains embryo-fetal toxicity/pregnancy risk; no AML/FLT3 indication language included.	Moderate
Daurismo is intended for patients with relapsed or refractory AML.	Not Addressed	No indication/relapsed-refractory AML information appears in the provided excerpt.	Moderate
In AML with FLT3 mutations, FLT3 signaling helps drive leukemia cell growth and survival.	Cannot Determine	Provided excerpt does not discuss FLT3 biology or mechanism in AML.	Informational
Daurismo targets FLT3.	Not Addressed	No mechanism/target information for FLT3 is present in the provided excerpt (it is focused on pregnancy risk).	Moderate
By inhibiting FLT3, Daurismo can slow or stop the growth signal in FLT3-mutated AML.	Not Addressed	No FLT3 inhibition or AML tumor-growth statement appears in the provided excerpt.	Moderate
For relapsed/refractory FLT3-mutated AML, the treatment goal with Daurismo is to achieve a disease response such as tumor/leukemia reduction.	Not Addressed	No efficacy goals, response criteria, or oncology outcome language appears in the provided excerpt.	Moderate
For relapsed/refractory FLT3-mutated AML, treatment with Daurismo is intended to improve outcomes compared with other available options for patients with this mutation profile.	Not Addressed	Provided excerpt does not include comparative effectiveness or outcome statements.	Moderate
Patients with AML are generally evaluated for FLT3 mutations to confirm eligibility before using gilteritinib.	Not Addressed	Provided excerpt does not discuss AML genetic testing or eligibility criteria.	Moderate

Important Omissions

No pregnancy/embryo-fetal toxicity risk mitigation statements were included in the AI’s FLT3/AML claims (the provided labeling excerpt emphasizes embryo-fetal risk and contraception/pregnancy testing/breastfeeding avoidance).

Unsupported / Hallucinated Content

DAURISMO = gilteritinib (contradicted by provided labeling stating DAURISMO is glasdegib).
All FLT3/AML-specific indication and mechanism claims are not supported by the provided pregnancy-focused labeling excerpt.

Potential Patient Safety Concerns

The combination of an incorrect drug identity (DAURISMO stated as gilteritinib) and missing pregnancy risk counseling could lead to confusion about the correct medication and associated reproductive risk information. The provided excerpt indicates DAURISMO (glasdegib) can cause embryo-fetal death or severe birth defects and requires pregnancy testing and contraception counseling.

Overall Assessment

The AI response is largely inconsistent with the provided authoritative labeling: it incorrectly equates DAURISMO with gilteritinib and makes multiple AML/FLT3-related claims that are not addressed in the provided embryo-fetal toxicity/pregnancy risk excerpt. The only clearly supported element from the provided labeling relates to pregnancy/embryo-fetal toxicity risk for DAURISMO (glasdegib), but this is not reflected in the AI’s oncology-focused claims.

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

It is used in acute myeloid leukemia (AML) when the leukemia has a FLT3 mutation

Core Claims

Daurismo is the brand name for gilteritinib.
It is used in acute myeloid leukemia (AML) with an FLT3 mutation.
It is intended for relapsed or refractory AML.
By inhibiting FLT3, Daurismo can slow or stop FLT3-mutated AML growth signal.
The treatment goal is to achieve a disease response and improve outcomes versus other available options for this mutation profile.

Differentiators

Targets FLT3 (fms-like tyrosine kinase 3).
Intended for FLT3-mutated relapsed/refractory AML.
Patients are generally evaluated for FLT3 mutations before using gilteritinib.

Pricing Perception: Not Mentioned